Skip to main content

Table 3 Discounted and undiscounted incremental lifetime effects of ERT versus no ERT treatment, overall and by gender (YFEOD: years free of end-organ damage; QALYs: quality adjusted life-years)

From: Cost-effectiveness of enzyme replacement therapy for Fabry disease

     Discount rate 1.5%      Discount rate 0%  
  ERT No ERT Difference ERT No ERT Difference
ALL       
 YFEOD 36.9 36.1 0.7 56.5 55.0 1.5
 QALYs 32.1 31.3 0.7 50.2 48.6 1.6
MALES       
 YFEOD 36.2 35.4 0.8 55.1 53.5 1.6
 QALYs 31.7 30.9 0.8 49.5 47.8 1.7
FEMALES       
 YFEOD 37.7 37.1 0.6 58.2 56.9 1.3
 QALYs 32.6 31.9 0.7 51.1 49.7 1.4